X4 Pharmaceuticals logo
X4 Pharmaceuticals
XFOR | NASDAQ
Chart Builder DCF Calculator
$2.83
-$0.29 (-9.29%)
At close: Nov 16, 2026, 4:00 PM ET
$2.84
+$0.01 (+0.35%)
After-hours: Nov 16, 2026, 7:30 PM ET

X4 Pharmaceuticals Company Profile

Company profile explained

Company Profile

X4 Pharmaceuticals, Inc. is a biopharmaceutical firm committed to the discovery, development, and commercialization of innovative therapies for uncommon immune system disorders. Its primary drug candidate, XOLREMDI (also known as mavorixafor), is an orally administered, small-molecule antagonist specifically designed to target the chemokine receptor CXCR4. This compound is currently undergoing Phase 3 clinical trials for the management of WHIM syndrome, a rare immunodeficiency characterized by symptoms such as warts, hypogammaglobulinemia, recurrent infections, and myelokathexis. To broaden its global presence, the company has entered into several licensing agreements: A partnership with Abbisko Therapeutics Co Ltd. grants rights for the manufacturing and distribution of XOLREMDI in mainland China, Taiwan, Hong Kong, and Macau. Another agreement with Norgine covers the development, production, and commercialization of mavorixafor across Europe, Australia, and New Zealand. Furthermore, X4 Pharmaceuticals holds a comprehensive agreement with Genzyme Corporation concerning the CXCR4 receptor, allowing for the development and commercialization of licensed compounds for all medical applications, including therapeutic, preventive, and diagnostic uses. The company maintains its corporate headquarters in Boston, Massachusetts.

Key Executives

Name Position
David H. Kirske Chief Financial Officer, Treasurer & Corporate Secretary
John Volpone President & Chief Operating Officer
Adam R. Craig Executive Chair
Keith T. Flaherty Founder & Member of Corporate Advisory Board
Renato T. Skerlj Founder
Richard Peters Founder

Latest SEC Filings

Date Type Title
Oct 29, 2026 8-K Current Report
Oct 19, 2026 4 Filing
Oct 08, 2026 8-K Current Report
Oct 07, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Oct 05, 2026 4 Filing
Sep 21, 2026 SC 13G Statement of acquisition of beneficial ownership b...
Sep 09, 2026 8-K Current Report
Sep 08, 2026 8-K Current Report
Aug 14, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Aug 14, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
View All SEC Filings ➞
X4 Pharmaceuticals
X4 Pharmaceuticals logo
Country United States
IPO Date Nov 16, 2017
Industry Biotechnology
Sector Healthcare
Employees 45
CEO Adam R. Craig

Contact Details

61 North Beacon Street Boston, Massachusetts 02134 United States

Stock Details

Ticker Symbol XFOR
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001501697
CUSIP Number 98420X202
ISIN Number US98420X2027
SIC Code 2836

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.